Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Lilly buys Siga's Priority Review voucher gained via smallpox approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/01/2018 | 09:11am EDT

Eli Lilly and Co. (NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga obtained in July upon approval of TPOXX tecovirimat to treat smallpox, was the first FDA awarded under its Material Threat Medical Countermeasure voucher program.

TPOXX, an oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga Gets Priority Review Voucher For First Approved Smallpox Drug").

Priority Review voucher prices have ranged from $67.5 million to $350 million since the first one was issued in 2009. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sold one in July for $80.6 million (see "Voucher Equilibrium" and "Kyowa, Ultragenyx Sell Priority Review Voucher For $80.6M").

The medical countermeasure program was created under the 21st Century Cures Act, and awards vouchers for "medical products intended to diagnose, prevent or treat diseases or conditions associated with threats and emerging infectious diseases."

Siga was up $0.27 to $5.10 in early trading Thursday.

.

(C) 2018 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 0.43% 118 Delayed Quote.1.97%
KIRIN HOLDINGS CO LTD -0.67% 2504.5 End-of-day quote.11.14%
KYOWA HAKKO KIRIN CO LTD -0.19% 2074 End-of-day quote.2.32%
SIGA TECHNOLOGIES, INC. -1.85% 5.3 Delayed Quote.-32.91%
ULTRAGENYX PHARMACEUTICAL INC -0.09% 67.73 Delayed Quote.55.77%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
08:38aELI LILLY AND : 4 Ways a Strong Patent System Benefits the U.S.
PU
07:03aELI LILLY AND : Lilly to Establish an Access Program for Patients as it Prepares..
PU
04/24ELI LILLY AND : Lilly Announces Sale of Legacy Antibiotics Brands and Manufactur..
AQ
04/23ELI LILLY AND : Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week..
AQ
04/23ELI LILLY AND : to Sell Legacy Antibiotics, Plant in China for $375 Million
DJ
04/22ELI LILLY AND : Lilly Announces Sale of Legacy Antibiotics Brands and Manufactur..
PR
04/22ELI LILLY AND : Invests in Avidity Biosciences As Part of New Collaboration
DJ
04/22ELI LILLY AND : Taltz Meets Primary, Secondary Phase 3 Endpoints
DJ
04/22ELI LILLY AND : Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week..
PR
04/22ELI LILLY AND : Lilly and Avidity Biosciences Announce Licensing and Research Co..
PR
More news
Financials ($)
Sales 2019 22 235 M
EBIT 2019 6 152 M
Net income 2019 4 303 M
Debt 2019 9 175 M
Yield 2019 2,09%
P/E ratio 2019 26,15
P/E ratio 2020 19,27
EV / Sales 2019 5,89x
EV / Sales 2020 5,41x
Capitalization 122 B
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 124 $
Spread / Average Target 5,5%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Michael R. Meadows VP & Chief Technology Officer
Aarti Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY1.97%121 698
JOHNSON & JOHNSON8.41%372 522
ROCHE HOLDING LTD.9.68%227 039
PFIZER-9.69%218 852
NOVARTIS7.44%195 750
MERCK AND COMPANY-2.20%192 697